## Laura Sciacovelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8691869/publications.pdf

Version: 2024-02-01

200 papers 11,957 citations

53 h-index 101 g-index

205 all docs 205 docs citations

times ranked

205

9230 citing authors

#	Article	IF	CITATIONS
1	Errors in Laboratory Medicine. Clinical Chemistry, 2002, 48, 691-698.	1.5	656
2	Errors in a Stat Laboratory: Types and Frequencies 10 Years Later. Clinical Chemistry, 2007, 53, 1338-1342.	1.5	501
3	Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clinical Chemistry and Laboratory Medicine, 2020, 58, 1070-1076.	1.4	496
4	Errors in clinical laboratories or errors in laboratory medicine?. Clinical Chemistry and Laboratory Medicine, 2006, 44, 750-9.	1.4	467
5	Mistakes in a stat laboratory: types and frequency. Clinical Chemistry, 1997, 43, 1348-1351.	1.5	462
6	The detection and prevention of errors in laboratory medicine. Annals of Clinical Biochemistry, 2010, 47, 101-110.	0.8	341
7	Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clinical Chemistry and Laboratory Medicine, 2008, 46, 764-72.	1.4	327
8	Preanalytical variability: the dark side of the moon in laboratory testing. Clinical Chemistry and Laboratory Medicine, 2006, 44, 358-65.	1.4	314
9	Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Annals of Emergency Medicine, 2016, 68, 76-87.e4.	0.3	294
10	IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clinica Chimica Acta, 2020, 507, 164-166.	0.5	279
11	The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1063-1069.	1.4	267
12	Preanalytical quality improvement: from dream to reality. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1113-26.	1.4	256
13	Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1081-1088.	1.4	253
14	Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. European Heart Journal, 2012, 33, 2001-2006.	1.0	233
15	Exploring the iceberg of errors in laboratory medicine. Clinica Chimica Acta, 2009, 404, 16-23.	0.5	203
16	How is cardiac troponin released from injured myocardium?. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 553-560.	0.4	179
17	Preanalytical quality improvement: in quality we trust. Clinical Chemistry and Laboratory Medicine, 2013, 51, 229-241.	1.4	162
18	The Brain-to-Brain Loop Concept for Laboratory Testing 40 Years After Its Introduction. American Journal of Clinical Pathology, 2011, 136, 829-833.	0.4	155

#	Article	IF	CITATIONS
19	Hemolyzed specimens: a major challenge for emergency departments and clinical laboratories. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 143-153.	2.7	151
20	Harmonization in laboratory medicine: the complete picture. Clinical Chemistry and Laboratory Medicine, 2013, 51, 741-751.	1.4	135
21	Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine, 2020, 62, 103101.	2.7	131
22	The IFCC Working Group on laboratory errors and patient safety. Clinica Chimica Acta, 2009, 404, 79-85.	0.5	126
23	Harmonization of quality indicators in laboratory medicine. A preliminary consensus. Clinical Chemistry and Laboratory Medicine, 2014, 52, 951-8.	1.4	116
24	Exploring the Initial Steps of the Testing Process: Frequency and Nature of Pre-Preanalytic Errors. Clinical Chemistry, 2012, 58, 638-642.	1.5	112
25	Errors in laboratory medicine and patient safety: the road ahead. Clinical Chemistry and Laboratory Medicine, 2007, 45, 700-7.	1.4	111
26	Quality Indicators in Laboratory Medicine: from theory to practice. Clinical Chemistry and Laboratory Medicine, 2011, 49, 835-844.	1.4	110
27	Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE). Clinical Chemistry and Laboratory Medicine, 2015, 53, 357-70.	1.4	110
28	Causes, consequences, detection, and prevention of identification errors in laboratory diagnostics. Clinical Chemistry and Laboratory Medicine, 2009, 47, 143-53.	1.4	106
29	Multicenter evaluation of the hemolysis index in automated clinical chemistry systems. Clinical Chemistry and Laboratory Medicine, 2009, 47, 934-9.	1.4	103
30	EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1281-5.	1.4	100
31	Diagnostic performances and thresholds: The key to harmonization in serological SARS-CoV-2 assays?. Clinica Chimica Acta, 2020, 509, 1-7.	0.5	99
32	Evaluation of Effectiveness of a Computerized Notification System for Reporting Critical Values. American Journal of Clinical Pathology, 2009, 131, 432-441.	0.4	87
33	Performance criteria and quality indicators for the pre-analytical phase. Clinical Chemistry and Laboratory Medicine, 2015, 53, 943-8.	1.4	86
34	Quality indicators to detect pre-analytical errors in laboratory testing. Clinical Biochemist Reviews, 2012, 33, 85-8.	3.3	83
35	Quality Indicators in Laboratory Medicine: the status of the progress of IFCC Working Group "Laboratory Errors and Patient Safety―project. Clinical Chemistry and Laboratory Medicine, 2017, 55, 348-357.	1.4	80
36	Laboratory network of excellence: enhancing patient safety and service effectiveness. Clinical Chemistry and Laboratory Medicine, 2006, 44, 150-60.	1.4	79

#	Article	IF	Citations
37	Defining a roadmap for harmonizing quality indicators in Laboratory Medicine: a consensus statement on behalf of the IFCC Working Group "Laboratory Error and Patient Safety―and EFLM Task and Finish Group "Performance specifications for the extra-analytical phases― Clinical Chemistry and Laboratory Medicine, 2017, 55, 1478-1488.	1.4	<b>7</b> 5
38	Harmonization of pre-analytical quality indicators. Biochemia Medica, 2014, 24, 105-113.	1.2	74
39	Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clinica Chimica Acta, 2021, 519, 60-63.	0.5	74
40	State of the art of BNP and NT-proBNP immunoassays: The CardioOrmoCheck study. Clinica Chimica Acta, 2012, 414, 112-119.	0.5	72
41	Towards a new paradigm in laboratory medicine: the five rights. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1881-1891.	1.4	70
42	Performance criteria and quality indicators for the post-analytical phase. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1169-1176.	1.4	69
43	Quality indicators in laboratory medicine: A fundamental tool for quality and patient safety. Clinical Biochemistry, 2013, 46, 1170-1174.	0.8	68
44	What to do when you question cardiac troponin values. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 577-586.	0.4	66
45	Interpretative commenting: A tool for improving the laboratory–clinical interface. Clinica Chimica Acta, 2009, 404, 46-51.	0.5	64
46	SARS-CoV-2 serosurvey in health care workers of the Veneto Region. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2107-2111.	1.4	64
47	The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology and clinical implications. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1634-1651.	1.4	63
48	Closing the brain-to-brain loop in laboratory testing. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1131-3.	1.4	59
49	SARS-CoV-2 identification and IgA antibodies in saliva: One sample two tests approach for diagnosis. Clinica Chimica Acta, 2020, 510, 717-722.	0.5	59
50	Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clinical Chemistry and Laboratory Medicine, 2009, 47, 762-8.	1.4	58
51	Quality Indicators for the Total Testing Process. Clinics in Laboratory Medicine, 2017, 37, 187-205.	0.7	58
52	Hemolysis index: quality indicator or criterion for sample rejection?. Clinical Chemistry and Laboratory Medicine, 2009, 47, 899-902.	1.4	57
53	Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomedica, 2020, 91, 137-145.	0.2	57
54	Promoting clinical and laboratory interaction by harmonization. Clinica Chimica Acta, 2014, 432, 15-21.	0.5	56

#	Article	IF	CITATIONS
55	Towards harmonization of quality indicators in laboratory medicine. Clinical Chemistry and Laboratory Medicine, 2013, 51, 187-195.	1.4	54
56	Harmonization in laboratory medicine: Requests, samples, measurements and reports. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 184-196.	2.7	52
57	Head-to-head comparison of plasma cTnI concentration values measured with three high-sensitivity methods in a large Italian population of healthy volunteers and patients admitted to emergency department with acute coronary syndrome: A multi-center study. Clinica Chimica Acta, 2019, 496, 25-34.	0.5	52
58	Laboratory critical values: Automated notification supports effective clinical decision making. Clinical Biochemistry, 2014, 47, 1163-1168.	0.8	50
59	The novel coronavirus (2019-nCoV) outbreak: think the unthinkable and be prepared to face the challenge. Diagnosis, 2020, 7, 79-81.	1.2	50
60	Appropriateness in programs for continuous quality improvement in clinical laboratories. Clinica Chimica Acta, 2003, 333, 131-139.	0.5	49
61	Assuring the quality of interpretative comments in clinical chemistry. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1901-1911.	1.4	49
62	SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1579-1586.	1.4	49
63	Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice. Advances in Clinical Chemistry, 2019, 93, 239-262.	1.8	46
64	Preanalytical challenges – time for solutions. Clinical Chemistry and Laboratory Medicine, 2019, 57, 974-981.	1.4	46
65	Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1444-1452.	1.4	46
66	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. Diagnostics, 2021, 11, 941.	1.3	45
67	The clinical importance of laboratory reasoning. Clinica Chimica Acta, 1999, 280, 35-45.	0.5	44
68	Interpretative reports and critical values. Clinica Chimica Acta, 2009, 404, 52-58.	0.5	44
69	Assessment of critical values policies in Italian institutions: comparison with the US situation. Clinical Chemistry and Laboratory Medicine, 2010, 48, 461-8.	1.4	43
70	External Quality Assessment: an effective tool for Clinical Governance in Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2006, 44, 740-9.	1.4	42
71	Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 79-90.	1.4	42
72	Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1727-37.	1.4	41

#	Article	IF	CITATIONS
73	Clinical laboratories: production industry or medical services?. Clinical Chemistry and Laboratory Medicine, 2015, 53, 995-1004.	1.4	41
74	To err is human. To misdiagnose might be deadly. Clinical Biochemistry, 2010, 43, 1-3.	0.8	40
75	Patient Safety and Quality in Laboratory and Hemostasis Testing: A Renewed Loop?. Seminars in Thrombosis and Hemostasis, 2012, 38, 553-558.	1.5	40
76	Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection. JAMA Network Open, 2022, 5, e2221616.	2.8	39
77	Strategies for the Early Diagnosis of Acute Myocardial Infarction Using Biochemical Markers. American Journal of Clinical Pathology, 1999, 111, 399-405.	0.4	38
78	Diagnostic Errors and Laboratory Medicine - Causes and Strategies. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2015, 26, 7-14.	0.7	38
79	The <i>CCLM</i> contribution to improvements in quality and patient safety. Clinical Chemistry and Laboratory Medicine, 2013, 51, 39-46.	1.4	37
80	Towards quality specifications in extra-analytical phases of laboratory activity. Clinical Chemistry and Laboratory Medicine, 2004, 42, 576-7.	1.4	36
81	An integrated system for monitoring the quality of sample transportation. Clinical Biochemistry, 2012, 45, 688-690.	0.8	36
82	Clinical relevance of biological variation of cardiac troponins. Clinical Chemistry and Laboratory Medicine, 2021, 59, 641-652.	1.4	36
83	Harmonization in laboratory medicine: more than clinical chemistry?. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1579-1586.	1.4	35
84	Quality in laboratory medicine: 50years on. Clinical Biochemistry, 2017, 50, 101-104.	0.8	34
85	New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clinical Biochemistry, 1996, 29, 67-72.	0.8	33
86	National survey on critical values reporting in a cohort of Italian laboratories. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1411-3.	1.4	33
87	Quality specifications in EQA schemes: from theory to practice. Clinica Chimica Acta, 2004, 346, 87-97.	0.5	32
88	Pre-analytical quality indicators in laboratory medicine: Performance of laboratories participating in the IFCC working group "Laboratory Errors and Patient Safety―project. Clinica Chimica Acta, 2019, 497, 35-40.	0.5	32
89	Short-term biological variation and diurnal rhythm of cardiac troponin I (Access hs-TnI) in healthy subjects. Clinica Chimica Acta, 2020, 504, 163-167.	0.5	32
90	Integrated diagnostics. Biochemia Medica, 2020, 30, 18-30.	1.2	32

#	Article	IF	CITATIONS
91	Risk management in laboratory medicine: quality assurance programs and professional competence. Clinical Chemistry and Laboratory Medicine, 2007, 45, 756-65.	1.4	31
92	An approach for estimating measurement uncertainty in medical laboratories using data from long-term quality control and external quality assessment schemes. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1696-1701.	1.4	31
93	External quality assessment programs in the context of ISO 15189 accreditation. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1644-1654.	1.4	31
94	Interpretative comments and reference ranges in EQA programs as a tool for improving laboratory appropriateness and effectiveness. Clinica Chimica Acta, 2003, 333, 209-219.	0.5	30
95	Quality indicators for laboratory diagnostics: consensus is needed. Annals of Clinical Biochemistry, 2011, 48, 479-479.	0.8	30
96	Quality and future of clinical laboratories: the Vico's whole cyclical theory of the recurring cycles. Clinical Chemistry and Laboratory Medicine, 2018, 56, 901-908.	1.4	30
97	Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1926-1935.	1.4	30
98	Driving the route of laboratory medicine: a manifesto for the future. Internal and Emergency Medicine, 2019, 14, 337-340.	1.0	29
99	Effects of sample transportation on commonly requested laboratory tests. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1755-60.	1.4	28
100	Biochemical markers of cardiac damage: from efficiency to effectiveness. Clinica Chimica Acta, 2001, 311, 3-7.	0.5	27
101	Brazilian laboratory indicators program. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1923-1934.	1.4	27
102	Improving diagnosis and reducing diagnostic errors: the next frontier of laboratory medicine. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1117-1118.	1.4	27
103	Performance specifications for the extra-analytical phases of laboratory testing: Why and how. Clinical Biochemistry, 2017, 50, 550-554.	0.8	27
104	External Quality Assessment Schemes: need for recognised requirements. Clinica Chimica Acta, 2001, 309, 183-199.	0.5	26
105	Improving the post-analytical phase. Clinical Chemistry and Laboratory Medicine, 2010, 48, 435-6.	1.4	26
106	Appropriate labelling of blood collection tubes: a step ahead towards patient's safety. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1921-3.	1.4	26
107	Monitoring quality indicators in laboratory medicine does not automatically result in quality improvement. Clinical Chemistry and Laboratory Medicine, 2012, 50, 463-9.	1.4	26
108	Innovative software for recording preanalytical errors in accord with the IFCC quality indicators. Clinical Chemistry and Laboratory Medicine, 2017, 55, e51-e53.	1.4	26

#	Article	IF	CITATIONS
109	What information on measurement uncertainty should be communicated to clinicians, and how?. Clinical Biochemistry, 2018, 57, 18-22.	0.8	26
110	Laboratory applications for smartphones: Risk or opportunity?. Clinical Biochemistry, 2011, 44, 273-274.	0.8	24
111	Utilization management: A European perspective. Clinica Chimica Acta, 2014, 427, 137-141.	0.5	24
112	Evaluating laboratory diagnostic tests and translational research. Clinical Chemistry and Laboratory Medicine, 2010, 48, 983-988.	1.4	23
113	Pilot study on harmonization of cardiac troponin I immunoassays using patients and quality control plasma samples. On behalf of the Italian Section of the European Ligand Assay Society (ELAS) and of the Study Group on Cardiovascular Biomarkers of the Società Italiana di Biochimica Clinica (SIBioC). Clinica Chimica Acta. 2016. 456. 42-48.	0.5	23
114	Clinical laboratory: bigger is not always better. Diagnosis, 2018, 5, 41-46.	1.2	23
115	Serum or plasma? An old question looking for new answers. Clinical Chemistry and Laboratory Medicine, 2020, 58, 178-187.	1.4	23
116	Harmonization of Clinical Laboratory Information - Current and Future Strategies. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 15-22.	0.7	23
117	The quality indicator paradox. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1119-1122.	1.4	22
118	Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1333-1335.	1.4	22
119	Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clinica Chimica Acta, 1994, 226, 151-158.	0.5	21
120	Once upon a time: a tale of ISO 15189 accreditation. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1127-9.	1.4	21
121	Universal screening of high-risk neonates, parents, and staff at a neonatal intensive care unit during the SARS-CoV-2 pandemic. European Journal of Pediatrics, 2020, 179, 1949-1955.	1.3	21
122	New issues on measurement of B-type natriuretic peptides. Clinical Chemistry and Laboratory Medicine, 2017, 56, 32-39.	1.4	20
123	Measurement uncertainty in laboratory reports: A tool for improving the interpretation of test results. Clinical Biochemistry, 2018, 57, 41-47.	0.8	20
124	Cardiac troponin I in SARS-CoV-2-patients: The additional prognostic value of serial monitoring. Clinica Chimica Acta, 2020, 511, 75-80.	0.5	20
125	An Italian External Quality Assessment (EQA) program on urinary sediment. Clinica Chimica Acta, 2010, 411, 859-867.	0.5	19
126	Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1885-1888.	1.4	19

#	Article	IF	CITATIONS
127	SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays. Clinica Chimica Acta, 2021, 523, 446-453.	0.5	19
128	Reference Intervals: Are Interlaboratory Differences Appropriate?. Clinical Chemistry and Laboratory Medicine, 1999, 37, 1131-3.	1.4	18
129	Laboratory-associated and diagnostic errors: a neglected link. Diagnosis, 2014, 1, 89-94.	1.2	18
130	Reporting altered test results in hemolyzed samples: is the cure worse than the disease?. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1112-1114.	1.4	18
131	Extra-analytical quality indicators and laboratory performances. Clinical Biochemistry, 2017, 50, 632-637.	0.8	18
132	Obese phenotype and natriuretic peptides in patients with heart failure with preserved ejection fraction. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1015-1025.	1.4	18
133	Evaluation of reproducibility of the cTnT immunoassay using quality control samples. Clinica Chimica Acta, 2019, 495, 269-270.	0.5	18
134	Quality Control in Coagulation Testing. Seminars in Thrombosis and Hemostasis, 2008, 34, 642-646.	1.5	17
135	ISO 15189 Accreditation: Navigation Between Quality Management and Patient Safety. Journal of Medical Biochemistry, 2017, 36, 225-230.	0.7	17
136	Decision Support and Patient Safety. Clinics in Laboratory Medicine, 2019, 39, 231-244.	0.7	17
137	SARS-CoV-2 antibodies titration: a reappraisal. Annals of Translational Medicine, 2020, 8, 1032-1032.	0.7	17
138	Diabetes alert dogs: a narrative critical overview. Clinical Chemistry and Laboratory Medicine, 2019, 57, 452-458.	1.4	15
139	Towards the rational utilization of SARS-CoV-2 serological tests in clinical practice. Clinical Chemistry and Laboratory Medicine, 2020, 58, e189-e191.	1.4	15
140	Extra-analytical quality indicators – where to now?. Clinical Chemistry and Laboratory Medicine, 2018, 57, 127-133.	1.4	14
141	Analytical quality: an unfinished journey. Clinical Chemistry and Laboratory Medicine, 2018, 56, 357-359.	1.4	14
142	Laboratory medicine in the COVID-19 era: six lessons for the future. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1035-1045.	1.4	14
143	Precipitation method for separating and quantifying bone and liver alkaline phosphatase isoenzymes. Clinical Biochemistry, 1991, 24, 417-423.	0.8	13
144	Medical Errors: Pre-Analytical Issue in Patient Safety. Journal of Medical Biochemistry, 2010, 29, 310-314.	0.7	13

#	Article	IF	Citations
145	The use of extra-analytical phase quality indicators by clinical laboratories: the results of an international survey. Clinical Chemistry and Laboratory Medicine, 2016, 54, e315-e317.	1.4	13
146	Performance specifications of critical results management. Clinical Biochemistry, 2017, 50, 617-621.	0.8	13
147	Laboratory-related errors: you cannot manage what you don't measure. You manage what you know and measure. Diagnosis, 2017, 4, 193-195.	1.2	12
148	Evaluation of an ELISA for SARS-CoV-2 antibody testing: clinical performances and correlation with plaque reduction neutralization titer. Clinical Chemistry and Laboratory Medicine, 2020, 58, e247-e249.	1.4	12
149	Rethinking internal quality control: the time is now. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1316-1317.	1.4	12
150	The importance of incident reporting in laboratory diagnostics. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 811-814.	0.6	11
151	Performance specifications in extra-analytical phase of laboratory testing: Sample handling and transportation. Clinical Biochemistry, 2017, 50, 574-578.	0.8	11
152	Understanding and managing interferences in clinical laboratory assays: the role of laboratory professionals. Clinical Chemistry and Laboratory Medicine, 2020, 58, 350-356.	1.4	11
153	Clinical performances of an ELISA for SARS-CoV-2 antibody assay and correlation with neutralization activity. Clinica Chimica Acta, 2020, 510, 654-655.	0.5	11
154	Extra-analytical sources of uncertainty: which ones really matter?. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1488-1493.	1.4	10
155	Measurement uncertainty $\hat{a} \in \hat{a}$ a revised understanding of its calculation and use. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1277-9.	1.4	9
156	Use of high-sensitivity cardiac troponins in the emergency department for the early rule-in and rule-out of acute myocardial infarction without persistent ST-segment elevation (NSTEMI) in Italy. Clinical Chemistry and Laboratory Medicine, 2021, .	1.4	9
157	SARS-CoV-2 antibody-based SURVEILLANCE: New light in the SHADOW. EBioMedicine, 2020, 61, 103087.	2.7	8
158	High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. Clinical Chemistry and Laboratory Medicine, 2021, 59, 513-521.	1.4	8
159	Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. Clinical Chemistry and Laboratory Medicine, 2021, 59, 51-57.	1.4	8
160	Evaluation of clinical cases in External Quality Assessment Scheme (EQAS) for the urinary sediment. Clinical Chemistry and Laboratory Medicine, 2014, 52, 845-52.	1.4	7
161	The Italian External Quality Assessment (EQA) program on urinary sediment: results of the period 2012–2015. Clinical Chemistry and Laboratory Medicine, 2015, 53, s1495-502.	1.4	7
162	Harmonization in laboratory medicine: Blowin' in the wind. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1559-1562.	1.4	7

#	Article	IF	Citations
163	Antibody responses in mild COVID-19 hospital staff. EBioMedicine, 2020, 59, 102940.	2.7	7
164	Measurement uncertainty: light in the shadows. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1381-1383.	1.4	7
165	External Quality Assessment for biochemical markers of myocardial damage: an Italian experience. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1434-41.	1.4	6
166	Total testing process: roots and state-of-the-art. Diagnosis, 2020, 7, 19-20.	1.2	6
167	The University of Padua salivary-based SARS-CoV-2 surveillance program minimized viral transmission during the second and third pandemic wave. BMC Medicine, 2022, 20, 96.	2.3	6
168	Assessment of Package Inserts for Diagnostic Kits. Clinical Chemistry and Laboratory Medicine, 1999, 37, 663-5.	1.4	5
169	Critical Laboratory Results: Communication Is Just One of the ProblemsThe Author's Reply. American Journal of Clinical Pathology, 2012, 137, 164-165.	0.4	5
170	SARS-CoV-2 antibody assay after vaccination: one size does not fit all. Clinical Chemistry and Laboratory Medicine, 2021, 59, e380-e381.	1.4	5
171	Serological diagnostic for SARS-CoV-2: an experimental External Quality Assessment Scheme. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1878-1884.	1.4	5
172	SARS-CoV-2 antibody performances: we need better criteria. Clinical Chemistry and Laboratory Medicine, 2020, 58, e303-e305.	1.4	5
173	Preanalytical quality improvement– an interdisciplinary journey. Clinical Chemistry and Laboratory Medicine, 2022, 60, 662-668.	1.4	5
174	Quality performance of laboratory testing in pharmacies: a collaborative evaluation. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1745-1751.	1.4	4
175	The silk road to total quality in Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2019, 57, 769-772.	1.4	4
176	Virucidal effects of mouthwashes or mouth rinses: a world of caution for molecular detection of SARS-CoV-2 in saliva. Diagnosis, 2022, 9, 285-287.	1.2	4
177	Clinical Chemistry and Laboratory Medicine: enjoying the present and assessing the future. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1313-1315.	1.4	4
178	Guidelines for acute coronary syndrome without ST elevation. Lancet, The, 2002, 359, 1350.	6.3	3
179	Notification of Abnormal and Critical Values: The Road Ahead. American Journal of Medicine, 2010, 123, e19.	0.6	3
180	Critical results communication: Still an open issue. Clinical Biochemistry, 2013, 46, 184.	0.8	3

#	Article	IF	Citations
181	Harmonization of units and reference intervals of plasma proteins: state of the art from an External Quality Assessment Scheme. Clinical Chemistry and Laboratory Medicine, 2018, 57, 95-105.	1.4	3
182	Performance evaluation of 14 specific proteins measurement checked by an External Quality Assessment Scheme. Clinica Chimica Acta, 2020, 502, 73-83.	0.5	3
183	SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology. Frontiers in Immunology, 2021, 12, 682850.	2.2	3
184	External quality assessment programs: Past, present and future. Journal of Medical Biochemistry, 2005, 24, 201-206.	0.1	3
185	Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease. Frontiers in Pediatrics, 2022, 10, 815857.	0.9	3
186	High-performance liquid chromatography for cyclosporin measurement: comparison with radioimmunoassay. Journal of Chromatography A, 1989, 476, 93-98.	1.8	2
187	Appropriateness of cholesterol and triglycerides reporting checked by External Quality Assessment programs. Clinica Chimica Acta, 2003, 333, 221-230.	0.5	2
188	Test Utilization Is a Quality Control Issue. American Journal of Clinical Pathology, 2015, 143, 910-911.	0.4	2
189	Laboratory Critical Values Should Support Effective Clinical Decision MakingThe Authors' Reply. American Journal of Clinical Pathology, 2016, 145, 142-144.	0.4	2
190	Improving clinical laboratory performance through quality indicators. Clinical Biochemistry, 2017, 50, 547-549.	0.8	2
191	The Italian External Quality Assessment (EQA) program on urinary sediment by microscopy examination: a 20 years journey. Clinical Chemistry and Laboratory Medicine, 2021, 59, 845-856.	1.4	2
192	Call for Enrolling More Professionals in the IFCC Project on Laboratory Errors and Patient Safety. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2011, 22, 1-5.	0.7	2
193	Transdermal measurement of cardiac troponins: the future is now. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1133-1135.	1.4	2
194	Reduction of unsuitable specimens: A more radical and comprehensive approach is needed. Clinica Chimica Acta, 2011, 412, 400.	0.5	1
195	A pilot study for establishing quality indicators in molecular diagnostics according to the IFCC WG-LEPS initiative: preliminary findings in China. Clinical Chemistry and Laboratory Medicine, 2019, 57, 822-831.	1.4	1
196	Assessment and monitoring of agreement among professionals for morphological evaluation in compliance with International accreditation standard requirements. Clinica Chimica Acta, 2020, 501, 72-82.	0.5	1
197	Two rapid SARS-CoV-2 disposable devices for semi-quantitative S-RBD antibody levels determination compared with CLIA and ELISA assays at different protective thresholds. Clinica Chimica Acta, 2022, 529, 104-108.	0.5	1
198	Reply to W.G. Wood. Questionable results – who directs the EQAS organisers? Clin Chem Lab Med 2004;42:1073. Clinical Chemistry and Laboratory Medicine, 2005, 43, 346-8.	1.4	0

#	Article	IF	CITATIONS
199	Different approaches for estimating measurement uncertainty: An effective tool for improving interpretation of results. Clinica Chimica Acta, 2020, 503, 223-227.	0.5	О
200	La gestione del rischio nei laboratori di patologia clinica e microbiologia. , 2013, , 191-203.		0